Product Images Lovastatin

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 5 images provide visual information about the product associated with Lovastatin NDC 68001-315 by Bluepoint Laboratories, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Lovastatin 10mg 100ct label - image 01

Lovastatin 10mg 100ct label - image 01

This appears to be a partial label for medication called Lovastatin, manufactured by Lupin Limited. The label includes the National Drug Code, dosage instructions, and storage information. The tablets come in child-resistant packaging and are intended for prescription use. The label warns to protect the medication from light and temperature extremes. However, the text is difficult to read due to errors from .*

Lovastatin 20mg 100ct label - image 02

Lovastatin 20mg 100ct label - image 02

This text describes a container containing 100 tablets of Lovastatin (Tovastatin USP) 20 mg each, manufactured by Suebont Laboratories with a child-resistant closure at room temperature and protected from light. The package insert provides complete prescribing information. The NDC is 68001-315-00, and the tablets come in an unvarnished area.*

Lovastatin 40mg 100ct label - image 03

Lovastatin 40mg 100ct label - image 03

This is a description of Lovastatin Tablets USP, a medication used to reduce high cholesterol levels. It comes in a pack of 100 tablets and each tablet contains 40mg of Lovastatin. The containers should be stored at controlled room temperature, protected from light and in a tight, light-resistant container. The usual dosage should be determined by a healthcare professional and the package insert should be consulted for complete prescribing information. The manufacturer is Lupin Limited.*

lovastatin - lovastatintabusp figure 01

lovastatin - lovastatintabusp figure 01

Figure 1 - lovastatintabusp figure 02

Figure 1 - lovastatintabusp figure 02

The text describes a figure with the title "Acute Major Coronary Events" and a primary endpoint. The figure shows a reduction in risk percentage of 87% with a statistical significance of p<0009 in the proportion of participants without an event. The x-axis of the figure represents years of follow-up.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.